

## **ASX Announcement**

## **Research Report**

**MELBOURNE Australia 10 April 2017:** AdAlta Limited (ASX: 1AD) advises Patersons Securities has published updated research coverage on the Company. A copy of the 13 page research report and other recent analyst reports are available on the Company's website: <http://adalta.com.au/investors/analyst-reports/>

Publication of the research report follows achievement of several important development milestones for the Company's lead drug candidate AD-114 targeting Idiopathic Pulmonary Fibrosis.

Earlier this year AdAlta was granted Orphan Drug Designation by the US Food & Drug Administration for its Idiopathic Pulmonary Fibrosis (IPF) program after presenting its preclinical data to the regulator.

## **Notes to editors**

AdAlta Limited (ASX:1AD) is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AD-114 has strong pre-clinical results for IPF, demonstrating both anti-fibrotic and anti-inflammatory activity in human lung tissue and indicating greater efficacy than existing approved IPF drugs.

AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases.

## **Contact:**

### **At AdAlta**

Sam Cobb  
Chief Executive Officer  
AdAlta Limited  
Tel: +61 (0) 3 9479 5159  
E: s.cobb@adalta.com.au

### **Media (Australia)**

Andrew Geddes  
Tel: +61 (0) 408 677 734  
E: adalta@instinctif.com

### **Media (International)**

Sue Charles/Daniel Gooch  
Tel: +44 (0) 20 7866 7905  
E: adalta@instinctif.com